| Migraine

Multiple, Once-daily, Oral Doses of 170 Mg Atogepant for 28 Days Are Safe and Well Tolerated with No Clinically Significant Effect on Alanine Aminotransferase in Healthy Adults

book_2 Source: AHSAM 2020 - Oral session Published on September 3, 2020
calendar_today Published on Medfyle: July 2020
import_contacts 7 min
headphones 2 min

In this medfyle

Expert commentary by Jessica Ailani, MD

This Medfyle was published more than two years ago. More recent Medfyle on this topic may now be available.

Read more arrow_downward Hide arrow_upward

This is a highlights summary of an oral session given at the AHSAM 2020 Virtual Annual Scientific Meeting and presented by:

K. Chris Min, MD, PhD
Formerly of Merck & Co., Inc.
Kenilworth, New Jersey

The content is produced by Infomedica, the official reporting partner of ASHAM 2020 Virtual Annual Scientific Meeting. The summary text was drafted by Goldcrest Medical Writing, reviewed by Marco Vercellino, MD, an independent external expert, and approved by Jessica Ailani, MD, FAHS and Mark J. Burish, MD, PhD, the scientific editors of the program.

The presenting authors of the original session had no part in the creation of this conference highlights summary.

In addition, an expert commentary on the topic has been provided by:

Jessica Ailani, MD, FAHS, FAAN
Director, Medstar Georgetown Headache Center
Vice Co-Chair Strategic Planning Medstar Neurology
Professor of Clinical Neurology
Medstar Georgetown University Hospital, Washington D.C. USA

About the Expert
Read more arrow_downward Hide arrow_upward

Jessica Ailani, MD
Director Medstar Georgetown Headache Center, Associate Professor Neurology
Department of Neurology, Georgetown University Hospital
Washington D.C., District of Columbia

Jessica Ailani is a Professor of Clinical Neurology, Director of the Georgetown Headache Center, and Vice Co-Chair of Strategic planning Neurology at MedStar Georgetown University Hospital in Washington, DC. Dr. Ailani is a fellow of the American headache society and the American Academy of Neurology. She holds a position on the board as a member at large, is the co-chair of the Practice management group and is on the scientific and Scottsdale program planning committees . She is section editor of Unusual Headache Syndromes for Current Pain and Headache Reports and a reviewer for several professional journals. Dr. Ailani has presented nationally on topics surrounding headache medicine. 

Read more arrow_downward Hide arrow_upward

1. Goadsby PJ, Holland PR, Martins-Oliveira M, et al. Pathophysiology of Migraine: A Disorder of Sensory Processing. Physiol Rev 2017;97:553-622.

2. Goadsby PJ, Dodick DW, Trugman JM, et al. Orally Administered Atogepant Was Efficacious, Safe, and Tolerable for the Prevention of Migraine: Results From a Phase 2b/3 Study (S17.001). Neurology 2019; 92(15 Supplement): S17.001.

3. Ho TW, Connor KM, Zhang Y, et al. Randomized controlled trial of the CGRP receptor antagonist telcagepant for migraine prevention. Neurology 2014;83:958-966.

4. Ho TW, Ho AP, Ge YJ, et al. Randomized controlled trial of the CGRP receptor antagonist telcagepant for prevention of headache in women with perimenstrual migraine. Cephalalgia 2016;36:148-161.